Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

Inclusion Criteria : * Healthy male or female subject, aged ≥ 18 to \< 50 years on the day of inclusion * Informed consent form signed * Able to attend all scheduled visits and to comply with all trial procedures * For a woman of childbearing potential: a negative urine pregnancy test and documented use of an effective method of contraception or abstinence for at least four weeks pre vaccination and up until three weeks post-vaccination Exclusion Criteria : * Subject currently breast-feeding. * Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the trial vaccination. * Planned participation in another clinical trial during the present trial period. * Prior participation in the Phase I trial of FLU INTERPAN (PER.C6) vaccine (study GCE01). * Congenital or history of acquired immunodeficiency, or immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months. * Systemic corticosteroid therapy as except the use of topical or inhalant corticosteroids * Systemic hypersensitivity to egg proteins, chicken proteins, or to any of the vaccine components, or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances. * Chronic illness at a stage that could interfere with trial conduct or completion (chronic illness may include, but is not limited to, cardiac, renal or auto-immune disorders, or diabetes). * Receipt of blood or blood-derived products in the 3 months preceding vaccination. * Receipt of any vaccination in the 4 weeks preceding vaccination, or planned receipt of any vaccination in the 4 weeks following the trial vaccination. * History of influenza infection (confirmed either clinically, serologically or microbiologically) within the 6 months preceding vaccination. * Previous vaccination against influenza (in the 6 months preceding the trial vaccination). * Planned receipt of any other 2007-2008 influenza vaccine. * Thrombocytopenia or bleeding disorder contraindicating intramuscular (IM) vaccination. * Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent. * History of Guillain-Barré syndrome * Current abuse of alcohol or drug addiction that may interfere with the subject's ability to comply with trial procedures * Any other condition which in the opinion of the investigator would pose a health risk to the participant or interfere with the evaluation of the vaccine.